Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Condensed Interim Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited)

v3.21.2
Condensed Interim Consolidated Statements of Shareholders' Equity (Deficit) (Unaudited) - USD ($)
$ in Thousands
Share Capital [Member]
Contributed Surplus - Warrant Reserve [Member]
Contributed Surplus [Member]
Deficit [Member]
Total
Beginning balance at Dec. 31, 2019 $ 194,217 $ 642 $ 8,304 $ (214,845) $ (11,682)
Beginning balance, share at Dec. 31, 2019 39,907,681        
Statement Line Items [Line Items]          
Issued pursuant to agency agreement $ 12,819       12,819
Issued pursuant to agency agreement, shares 23,923,700        
March 2020 Equity Offering - broker warrants $ (26) 26      
Common stock equivalents converted $ 1       1
Common stock equivalents converted, shares 11,500,000        
Share issue expense $ (488)       (488)
Warrants exercised $ 5,900       5,900
Warrants exercised, shares 6,217,939        
Stock-based compensation expense     721   721
Net loss       (3,552) (3,552)
Ending balance at Sep. 30, 2020 $ 212,423 668 9,025 (218,397) 3,719
Ending balance, shares at Sep. 30, 2020 81,549,320        
Beginning balance at Dec. 31, 2020 $ 214,148 1,671 9,401 (239,029) (13,809)
Beginning balance, share at Dec. 31, 2020 83,184,843        
Statement Line Items [Line Items]          
Derivative warrants exercised $ 8,000       8,000
Derivative warrants exercised, shares 8,000,000        
Derivative warrants exercised - fair value adjustment $ 15,722       15,722
January 2021 Equity Offering, net of issuance costs $ 7,211 3,164     10,375
January 2021 Equity Offering, net of issuance costs, shares 7,419,354        
January 2021 Equity Offering-broker warrants $ (1,384) 1,384      
February 2021 Equity Offering, net of issuance costs $ 15,165 5,928     21,093
February 2021 Equity Offering, net of issuance costs, shares 9,585,250        
February 2021 Equity Offering-broker warrants $ (1,238) 1,238      
Equity warrants exercised $ 1,985       1,985
Equity warrants exercised, shares 1,318,675        
Options exercised $ 27   (13)   14
Options exercised, shares 19,568        
Issuance of common shares to Aspire $ 2,709       2,709
Issuance of common shares to Aspire, shares 1,600,000        
Stock-based compensation expense     3,645   3,645
Net loss       (24,289) (24,289)
Ending balance at Sep. 30, 2021 $ 262,345 $ 13,385 $ 13,033 $ (263,318) $ 25,445
Ending balance, shares at Sep. 30, 2021 111,127,690       111,127,690